BariaTek

BariaTek is a clinical-stage MedTech company founded in 2019 by Truffle Capital. The company specializes in developing innovative medical devices aimed at combating obesity and diabetes, which affect over a billion people globally. BariaTek focuses on creating minimally invasive, endoscopically implanted devices that replicate the effects of bariatric surgery without traditional surgical procedures. Their flagship product, BariTon™, is a reversible implant designed to reduce food intake and decrease calorie absorption. It consists of a gastric component and an intestinal component, effectively mimicking the physiological effects of bariatric surgery. The BariTon™ implant can be inserted endoscopically in just a few minutes, providing a less invasive alternative to conventional weight loss surgeries. BariaTek is dedicated to the development, clinical testing, and commercialization of these advanced endoscopic implants, targeting healthcare providers specializing in obesity treatment and bariatric surgery centers. The company aims to offer effective solutions for patients seeking less invasive weight loss options.

• Employees 19
• Founded 2020
• Annual Revenue $3000000
• Total Funding $1598670